Cytokine networks—towards new therapies for rheumatoid arthritis
- 1 November 2005
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 1 (1) , 31-39
- https://doi.org/10.1038/ncprheum0020
Abstract
Success achieved so far in the blockade of tumor necrosis factor and interleukin (IL)-1 in rheumatoid arthritis exemplifies the feasibility and potential therapeutic application of antagonizing cytokine signaling. Despite these advances, there remains a considerable unmet clinical need in this field. A number of preclinical development programs are ongoing to target a variety of cytokines that are central to immune regulation and tissue-matrix destruction in rheumatoid arthritis. Evidence indicates that IL-6 antagonists might represents a useful approach and preliminary data similarly identify IL-15 as an intriguing target. Numerous additional cytokines are under investigation at the preclinical stage, including IL-12-IL-23, IL-17 and IL-18. As therapeutic goals move from disease control towards remission induction, development of the capacity for cytokine targeting to modify the underlying immune dysregulation remains a major priority.Keywords
This publication has 56 references indexed in Scilit:
- Interleukin-18 Promotes Joint Inflammation and Induces Interleukin-1-Driven Cartilage DestructionThe American Journal of Pathology, 2004
- Oncostatin M in combination with tumor necrosis factor α induces cartilage damage and matrix metalloproteinase expression in vitro and in vivoArthritis & Rheumatism, 2003
- New strategies to control inflammatory synovitis: interleukin 15 and beyondAnnals of the Rheumatic Diseases, 2003
- Interleukin 1 Receptor Dependence of Serum Transferred Arthritis Can be Circumvented by Toll-like Receptor 4 SignalingThe Journal of Experimental Medicine, 2003
- The balance of Th1/Th2 cytokines in rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2001
- Randomized, double-blind trial of anti-interferon-?antibodies in rheumatoid arthritisScandinavian Journal of Rheumatology, 2001
- Anti-interleukin 6 receptor antibody treatment in rheumatic diseaseAnnals of the Rheumatic Diseases, 2000
- Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritisEuropean Journal of Immunology, 1999
- THE MULTIFACETED REGULATION OF INTERLEUKIN-15 EXPRESSION AND THE ROLE OF THIS CYTOKINE IN NK CELL DIFFERENTIATION AND HOST RESPONSE TO INTRACELLULAR PATHOGENSAnnual Review of Immunology, 1999
- A randomized, double‐blind study comparing twenty‐four‐week treatment with recombinant interferon‐γ versus placebo in the treatment of rheumatoid arthritisArthritis & Rheumatism, 1997